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Vestergaard ET, Andersen NH, Hansen TK, Rasmussen LM,
Moller N, Sorensen KE, Sloth E, Jorgensen JO. Cardiovascular
effects of intravenous ghrelin infusion in healthy young men. Am J
Physiol Heart Circ Physiol 293: H3020–H3026, 2007. First published
September 14, 2007; doi:10.1152/ajpheart.00496.2007.—Ghrelin in-
fusion improves cardiac function in patients suffering from cardiac
failure, and bolus administration of ghrelin increases cardiac output in
healthy subjects. The cardiovascular effects of more continuous in-
travenous ghrelin exposure remain to be studied. We therefore studied
the cardiovascular effects of a constant infusion of human ghrelin at
a rate of 5 pmol/kg per minute for 180 min. Fifteen healthy, young
(aged 23.2  0.5 yr), normal-weight (23.0  0.4 kg/m2) men
volunteered in a randomized double-blind, placebo-controlled cross-
over study. With the subjects remaining fasting, peak myocardial
systolic velocity S, tissue tracking TT, left ventricular ejection
fraction EF, and endothelium-dependent flow-mediated vasodilatation
were measured. Ghrelin infusion increased S 9% (P 0.002) and TT
10% (P  0.001), whereas EF, resting blood flow velocity, and
endothelium-dependent flow-mediated vasodilatation did not change
(P 0.13). This was associated with a peak in serum growth hormone
after 60 min of infusion (37.77  5.27 ng/ml, P  0.001), a doubling
of free fatty acid levels (P 0.001), and a 1.6-fold increase in cortisol
levels (P  0.05), whereas glucose and catecholamine levels were
constant. In conclusion, supraphysiological levels of ghrelin stimulate
left ventricular function in terms of S and TT in healthy young
normal-weight men without changing resting blood flow velocity and
endothelium-dependent flow-mediated vasodilatation. The effects did
not translate into detectable increments in EF.
left ventricular function; tissue Doppler imaging; tissue tracking;
endothelium-dependent flow-mediated vasodilatation
GHRELIN IS THE ENDOGENOUS ligand for the growth hormone (GH)
secretagogue receptor type 1a (GHS-R1a) (27).
Administration of ghrelin is associated with a distinct stim-
ulation of GH secretion, but ghrelin also induces the release of
adrenocorticotropic hormone (ACTH) and prolactin (41).
The GHS-R1a and its mRNA are not only restricted to the
hypothalamus and the pituitary gland but are also located in
various human tissues including the myocardium (18, 21, 23,
33, 38). Ghrelin ([125I-His9]-ghrelin) demonstrates a saturable,
reversible, and high-affinity binding to human cardiovascular
tissue (23), and the highest binding activity of [125I]Tyr-Ala-
hexarelin (a synthetic GHS-R1a ligand) has been observed in
the myocardium (38).
In vitro, ghrelin protects the cardiomyocyte cell line H9c2
against doxorubicin-induced apoptosis (5), and, in vivo, ghre-
lin protects rat myocardium against isoproterenol-induced
myocardial injury (12) and reduces infarct size following
ischemia (17).
In healthy subjects, exogenous ghrelin injected as an intrave-
nous bolus acutely increases cardiac output (33). In a placebo-
controlled, randomized noncrossover study comprising 12 pa-
tients with chronic heart failure, a 60-min constant high-dose
infusion of ghrelin (more than 5 times the dose used in the
present study) improved cardiac and stroke volume index
concomitantly with a significant increase of epinephrine levels
and a decrease of cardiac afterload (34).
Besides putative direct cardiac effects, ghrelin may exert
indirect effects via an increase in GH (14, 33–35) and cate-
cholamine levels (33, 34) and a decrease in cardiac afterload
(33, 34). However, the cardiovascular effects have been inves-
tigated in subjects with high ghrelin levels only (more than 12
times higher than peak fasting levels) (14, 34).
Reports on the localization of the receptor for ghrelin (18,
21, 23, 33, 38) and on the cardiovascular effects of ghrelin (5,
12, 14, 17, 33–35) substantiate the importance to evaluate in
more details potential cardiovascular therapeutic applications
of exogenous ghrelin.
We hypothesize that ghrelin improves cardiovascular func-
tions independently of vasodilatation. In this randomized, dou-
ble-blind, and placebo-controlled crossover study, we investi-
gated the effects of more physiological increments in ghrelin
levels on left ventricular peak myocardial systolic velocity,
distance of motion along the Doppler axis (tissue tracking), and
endothelium-dependent vasodilatation in humans.
MATERIALS AND METHODS
Study Subjects
Fifteen healthy men, aged 23.2  0.5 yr with a body mass index of
23.0  0.4 kg/m2, volunteered for this study. The participants had no
history or present symptoms of cardiovascular disease, vasculitis, or
coagulopathy, and none were smokers, abusers of alcohol, or taking
any type of medication including aspirin. They all had a normal
physical examination including heart rate (61  2 per min) and blood
pressure (systolic 125  2, diastolic 79  2 mmHg). Fasting blood
glucose, triglycerides, and cholesterol levels, hematological, renal,
and hepatic functions assessed by biochemical screening were also
normal in all participants.
The study was conducted in accordance with the Helsinki Decla-
ration and all subjects gave their oral and written, informed consent to
participate. The study protocol was approved by the local Ethics
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Committee of Aarhus County, the Danish Medicines Agency and the
Good Clinical Practice (GCP) Unit of Aarhus University Hospital.
According to the International Committee of Medical Journal Editors,
the protocol was registered (Clinicaltrials.gov ID NCT00116025)
before the onset of enrollment.
Data focusing on pharmacokinetics from this study have previously
been published (45).
Preparation of Synthetic Ghrelin
Synthetic human acylated ghrelin (NeoMPS, Strasbourg, France)
was dissolved in isotonic saline and sterilized by double passage
through a 0.8- and 0.2-m-pore-size filter (Super Acrodisc, Gelman
Sciences, Ann Arbor, MI). The preparation was made by the local
hospital pharmacy.
Protocol
In a randomized double-blind and placebo-controlled crossover
design we used a 3-h constant infusion of human ghrelin (infusion
period t 0 to 180 min) of 5 pmol/kg per minute to investigate effects
on systolic myocardial velocities, tissue tracking (TT), left ventricular
ejection fraction, and flow-mediated vasodilatation of the radial artery
(FMD-R). Seven subjects were randomized to receive ghrelin on the
first and saline on the next study day. The remaining eight subjects
were randomized to the opposite treatment sequence. The study days
were separated by a minimum of 3 wk. Fasted subjects had two
intravenous cannulae inserted in the cubital regions: one for infusion,
and, in the contralateral arm, one for blood sampling. The intravenous
line was kept patent during both ghrelin and placebo administration by
infusion of an isovolumetric load of isotonic saline at a rate of 1.69
ml/kg body wt per hour. The subjects were studied in the supine
position from 8:00 AM during quiet, thermoneutral conditions. Echo-
cardiography was performed before infusion period (t  15), after
60 min (t  60), and after 165 min from onset of infusion (t  165).
Flow-mediated vasodilatation was measured on the right-hand side
before the infusion period (t  30) and after 150 min of infusion
(t  150). The subjects fasted during the trial.
Echocardiographic Study
Echocardiography. All subjects underwent an echocardiographic
examination performed by the same observer with all post hoc off-line
analyses being performed blinded to the randomization. Echocardi-
ography was performed on a GE Vivid Seven (GE Healthcare, Horten,
Norway) with a 2.5-MHz transducer, using second harmonic modal-
ities for enhanced endocardial border detection (24).
Tissue Doppler imaging. Tissue Doppler imaging was obtained
from the four- and two-chamber apical views and from the apical
long-axis view during end-expiration apnea.
The left ventricle was divided into 12 segments (septal, lateral,
anterior, inferoseptal, anteroseptal, and posterior segments at both the
basal and middle level) and the peak myocardial systolic velocities
and distance of motion for each segment were assessed. The peak
systolic velocity and distance of motion were assessed as the mean of
the values obtained from three consecutive heart cycles from each of
the 12 myocardial segments. The averages of the 12 segments are
presented and denoted S for peak systolic velocity and TT for the
distance of motion. The tissue Doppler technique in the present study
allowed processing of simultaneous S and TT from different myo-
cardial segments in the same cineloop.
TT displays the integral of tissue velocity during systole, which
equals the distance of motion along the Doppler axis (3, 37). TT
requires simultaneous ECG registration to define the beginning and
the end of the systole. Seven color bands indicate different distances
of motion with a stepwise increase in the distance of motion. The
range of distance of motion displayed by the seven color bands can be
altered depending on the left ventricular function, to stretch the color
bands between the apex and the mitral annular level. Analyzing the
left ventricle in apical views, the lowest distance of motion is at the
apex and the greatest at the mitral annulus.
Color noise reduction was adjusted and the tissue Doppler scanning
frame rates were kept above 160 frames per second in all cases (1).
Loading conditions were kept similar during ghrelin infusion and
placebo treatment (4).
Ejection fraction. Left ventricular ejection fraction was estimated
using Simpson’s modified biplane method, based on three measure-
ments. Endocardial border detection was enhanced by use of second
harmonic imaging (25, 29).
Vascular Study
Changes in the proximal right-hand-side radial artery diameter in
response to reactive hyperemia were measured right below the intra-
venous cannulae in the cubital region with high-resolution ultrasound
(Acuson Sequoia C256, Siemens, Mountain View, CA, with an
8-MHz linear array vascular transducer). Endothelium-dependent
flow-mediated vasodilatation of the radial artery was carried out as
previously recommended (13). After 30 min of rest, the intima-
media boundaries were identified manually and the baseline diameter
of the radial artery and the blood flow were recorded. Arterial blood
flow was estimated by calculating the velocity-time integral (VTI)
corresponding to the area under the Doppler curve. The transducer
was held in place by a stereotactic clamp, and a blood pressure cuff
was placed proximal to the cubital fossa and inflated to 280 mmHg.
After 5 min, the cuff was quickly deflated, whereafter a midartery
pulsed Doppler signal was obtained and artery diameter measure-
ments were taken for 2 consecutive min. A second measurement of
flow-mediated vasodilatation was performed just prior to termination
of the infusion period. Finally, endothelium-independent nitroglycer-
ine-mediated vasodilatation was performed 4 min after sublingual
administration of nitroglycerine spray (0.4 mg).
All images were digitized online and stored for later off-line
analyses. Straight segments of the artery (more than 10 mm if
possible) were chosen for analysis and the artery diameter was
measured at the same time in the cardiac cycle (with the R wave on
the ECG). All procedures were done, blinded to the randomization
sequence, by the same experienced observer. The image analysis and
measurement of the vasodilator response were performed in triplicate.
Biochemical Measurements
Serum ghrelin (total levels) were measured in duplicate by an
in-house assay as described previously (16). The assay measures
immunoreactive levels of ghrelin using 125I-labeled bioactive ghrelin
tracer and rabbit polyclonal antibodies raised against octanoylated
human ghrelin. The assay recognizes the COOH-terminal of ghrelin
and as such determines acylated as well as des-acylated ghrelin. The
intra-assay coefficient of variation averaged 2.8% and samples from
each individual were analyzed in one assay. A commercial double
monoclonal immunofluorometric assay (DELFIA, Perkin Elmer, Wal-
lac, Turku, Finland) was used to measure serum GH (s-GH), cortisol
(s-cortisol), and insulin (s-insulin). Plasma glucose (p-glucose) levels
were measured in duplicate on a glucose analyzer (Beckman Instru-
ments, Palo Alto, CA). Serum free fatty acids (s-FFA) were deter-
mined by use of a commercial kit (Wako Chemicals, Neuss, Ger-
many). Plasma catecholamines were measured by liquid chromatog-
raphy (15). Serum soluble intercellular cell adhesion molecule-1
(s-ICAM-1) and vascular cell adhesion molecule-1 (s-VCAM-1) were
measured by commercially available ELISA kits, as described by the
manufacturer (R&D Systems, Minneapolis, MN, catalogue nos.
BBE1B and DY809). Serum concentration of osteoprotegerin (OPG)
was measured in duplicate by a sandwich ELISA method (R&D
Systems, Minneapolis, MN, catalog no. DY805).
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Statistical Analysis
Results are expressed as means  SE. S, TT, and heart rate were
analyzed by two-way ANOVA. The treatment  time interaction was
considered the term of interest. The Bonferroni correction was used to
account for multiple comparisons. To adjust for the considerable (9)
pure biological, within-subject variability during the course of 1 day
in FMD-R, resting blood flow, peak hyperemic flow, and arterial
diameter, we compared the differences in FMD-R and the vascular
parameters during ghrelin treatment with differences observed during
placebo treatment. The trapezoidal rule was used to estimate area
under the concentration curve (AUC) levels for the hormones and
metabolites. FMD-R, hormones, and metabolites were examined by
Student’s two-tailed paired t-test. A P value 0.05 was chosen as
level of significance. All analyses were performed with SPSS version
14.0 for Windows.
RESULTS
Echocardiographic Study
The mean peak systolic velocities were similar at baseline in
the saline and ghrelin groups (Table 1). S increased by 9.1 
2.6% during the first 60 min of ghrelin infusion, P  0.007,
and the increase persisted throughout the study. S was con-
stant during saline infusion, P  0.17, Fig. 1. There was a
significant effect of ghrelin infusion on S, P (time  treat-
ment)  0.002.
The heart rates were comparable between groups and stable
over time, P (time  treatment)  0.69, Table 1.
Tissue Tracking
TT, reflecting the global longitudinal systolic contraction
amplitude of the left ventricle, increased significantly by
ghrelin infusion with 9.6  3.1 and 11.2  3.6% after 60,
P  0.013 and 165 min, P  0.010, respectively. TT was
unaffected by saline infusion, P  0.19, Fig. 2. Overall, we
found a significant effect of ghrelin infusion on TT, P (time 
treatment)  0.001.
Ejection Fraction
The three repeated measures of left ventricular ejection
fraction during ghrelin and saline infusion were similar,
P (time  treatment)  0.92, Table 2.
Vascular Study
VTI, peak hyperemic flow, diameter of the radial artery, and
the FMD-R at baseline were similar on each of the 2 study days
(see Table 3 for details).
When the delta values are compared from time t  30 to
150 min of ghrelin- and saline-infusion, neither ghrelin nor
saline had any effect on the vascular measurements including
FMD-R (Table 4).
Ghrelin infusion showed a trend to decrease VTI (t  30
min vs. t  150 min: P  0.08), whereas ghrelin infusion had
no effects on resting diameter of the radial artery, peak hyper-
emic blood flow, or FMD-R, P all 	 0.05.
Endothelium-independent (nitroglycerine-mediated) vasodi-
latation was also similar during ghrelin- (12.1  1.5%) and
saline-infusion (15.2  2.1%), P  0.13.
Fig. 2. Tissue tracking (TT) in the ghrelin (E) and placebo () groups at
different time points. Distances of motion along the Doppler axes are shown as
changes from baseline values. Printed P value refers to the interaction of time
and treatment of ghrelin on TT.
Table 1. Effects of ghrelin and saline (placebo) on systolic
velocities and tissue tracking
Time, min
Treatment
Ghrelin Placebo
Systolic velocity, cm/s
15 6.80.3 7.30.3
60 7.50.3 7.00.3
165 7.50.4 7.10.4
Tissue tracking, mm
15 11.50.4 12.10.3
60 12.50.4 11.80.3
165 12.70.5 11.90.3
Heart rate, per min
15 58.11.8 53.22.1
60 54.51.2 51.41.9
165 54.41.1 51.11.8
Values are means  SE.
Fig. 1. Systolic velocities (S) in the ghrelin (E) and placebo group () at
different time points. Velocities are shown as changes from baseline values.
Printed P value refers to the interaction of time and treatment of ghrelin on S.
H3022 CARDIOVASCULAR EFFECTS OF GHRELIN
AJP-Heart Circ Physiol • VOL 293 • NOVEMBER 2007 • www.ajpheart.org
 by 10.220.33.2 on January 9, 2017
http://ajpheart.physiology.org/
D
ow
nloaded from
 
Hormones and Metabolites
The effects of ghrelin infusion on hormones and metabolites
are reported in Table 5.
Baseline serum ghrelin levels were 0.72  0.06 g/l and
increased5.0- and 6.7-fold above baseline levels after 60 and
165 min, respectively.
Serum levels of GH and cortisol both peaked after 60 min,
both P  0.05, thereafter decreasing. Serum cortisol levels
were similar at t  165 min, P  0.054, whereas the level of
GH at this time point remained elevated by ghrelin infusion,
P  0.05. s-FFA levels reached a significantly higher level
during ghrelin infusion at t  165 min compared with placebo
infusion, whereas glucose levels were unaltered in this study,
P 0.90 and P 0.30 at t 60 and t 165 min, respectively.
Serum insulin levels were also unaffected by the infusion of
ghrelin at t  60 min, P  0.62, but increased at t  165 min,
P  0.05. Catecholamine levels were similar on the two
occasions, all P values 	0.05 for both epinephrine and nor-
epinephrine at t  60 and 165 min, respectively.
Markers of Endothelial Activation and Vascular
Matrix Changes
Serum levels of s-ICAM-1, s-VCAM-1, and OPG were
similar at baseline (ghrelin vs. placebo): 189.0  6.6 g/l vs.
198.1  9.2 g/l, P  0.054, 291.0  16.2 g/l vs. 296.8 
18.3 g/l, P 0.41, and 1.2 0.1 g/l vs. 1.3 0.2 g/l, P
0.30, respectively. Ghrelin infusion had no effect on the levels
of either of these analytes (ghrelin vs. saline): AUC for
s-ICAM-1 67.2  2.5 mg/l  min vs. 70.3  3.8 mg/l  min,
P  0.12, AUC for s-VCAM-1 104.9  6.0 mg/l  min vs.
104.2 6.3 mg/lmin, P 0.87, and AUC for OPG 414.8
54.8 g/l  min vs. 438.3  53.9 g/l  min, P  0.63.
DISCUSSION
The study shows that a constant ghrelin infusion stimulates
load-independent indexes of myocardial function such as the
left ventricular peak systolic velocity and contraction ampli-
tude without affecting resting blood flow in the radial artery or
endothelium-dependent flow-mediated vasodilatation. There
was no effect on conventional ejection fraction.
Acute inotropic effects have previously been shown after an
intravenous bolus administration of a pharmacological dose,
resulting in a 60-fold increase in systemic ghrelin levels (33),
and similar effects have been found in patients with congestive
heart failure (34, 35).
Besides putative direct cardiac effects, ghrelin may exert
indirect effects through an increase in GH (14, 33–35) or
catecholamine levels (33, 34), or via a decrease in cardiac
afterload (33, 34).
Ghrelin has been shown to improve endothelial dysfunction
by increasing endothelial nitric oxide (NO) release in GH-
deficient rats (40), as well as in patients with the metabolic
syndrome (42). Moreover, in healthy humans, intra-arterial
ghrelin showed GH- and NO-independent vasodilatory prop-
erties (36). Such endothelial-independent vasodilatory effects
of ghrelin may be mediated by physiological antagonism of
endothelin-1 (50).
Table 3. Baseline characteristics of resting VTI, peak
hyperemic flow, diameter of the radial artery, and FMD-R
at t  30 min on each of the 2 study days
Variable Ghrelin Placebo P
Resting VTI, cm 3.40.6 3.50.6 0.91
Peak hyperemic flow, % 1,121141 1,073137 0.71
Resting diameter, mm 2.600.09 2.570.10 0.67
FMD-R, % 7.41.2 9.21.4 0.22
Values are means  SE. VTI, velocity-time integral; FMD-R, flow-medi-
ated vaodilatation of the radial artery.
Table 2. Effects of ghrelin and saline on left ventricular
ejection fraction
Time, min
Treatment
Ghrelin Placebo
15 55.10.7 55.30.6
60 56.61.0 56.90.7
165 57.10.8 57.00.8
Values are means  SE. Ejection fraction is in percentage (%).
Table 4. Delta values of resting VTI, peak hyperemic flow,
diameter of the radial artery, and FMD-R from time t 
30 to 150 min of ghrelin- and saline-infusion, respectively
Variable Ghrelin Placebo P

Resting VTI, cm 0.50.3 0.20.3 0.22

Peak hyperemic flow, % 153108 3758 0.21

Resting diameter, mm 0.030.03 0.000.03 0.51

FMD-R, % 0.10.7 1.80.9 0.13
Values are means  SE.
Table 5. Circulating concentrations of ghrelin, growth
hormone, cortisol, insulin, epinephrine, norepinephrine,
glucose and free fatty acids in 15 healthy volunteers during
the infusion of ghrelin and placebo. * refers to P  0.05 by
post hoc comparison between ghrelin and placebo
15 min 60 min 165 min
Ghrelin, g/l
Ghrelin 0.720.06 3.930.24* 5.320.34*
Placebo 0.750.07 0.780.07 0.790.07
GH, ng/ml
Ghrelin 0.360.25 37.775.27* 8.521.81*
Placebo 0.740.47 1.590.64 0.940.26
Cortisol, nmol/l
Ghrelin 277.124.6 338.331.8* 290.326.9
Placebo 312.927.3 216.923.2 231.924.7
Insulin, pmol/l
Ghrelin 25.11.9 19.92.1 25.02.6*
Placebo 25.93.6 21.22.6 18.82.2
Epinephrine, pg/ml
Ghrelin 46.84.8 45.96.5 44.75.8
Placebo 38.54.5 37.33.9 41.48.3
Norepinephrine, pg/ml
Ghrelin 207.419.5 184.422.5 205.220.1
Placebo 205.228.4 197.318.1 220.826.6
Glucose, mmol/l
Ghrelin 4.90.1 5.00.1 5.30.1
Placebo 5.10.1 5.00.1 5.20.1
FFA, mmol/l
Ghrelin 0.390.05 0.590.07 1.040.09*
Placebo 0.340.05 0.440.07 0.510.07
Values are means  SE. *P  0.05 vs. placebo.
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In the present study s-GH increased rapidly in response to
ghrelin infusion, reaching the peak level after 60 min of
infusion and decreasing hereafter. The acute cardiovascular
effects (within hours) of GH are, if any, disputable (47, 51). In
normal cardiac myocytes GH neither increased intracellular
Ca2 nor increased contractility (26). There is more evidence
in support of GH-independent cardiovascular effects of ghre-
lin; in rodent studies, hexarelin and ghrelin, both independently
of GH, attenuated myocardial injury and left ventricular dys-
function after ischemia-reperfusion injury (11, 30), and in
GH-deficient patients an intravenous bolus of hexarelin im-
proved GH-independent left ventricular ejection fraction (7, 8).
G protein-coupled receptor (GPCR) activation initiates car-
diomyocyte signaling, leading to adaptive cardiac function.
Included among the cardiac GPCR is the most widespread
ghrelin receptor GHS-R1a (23, 38). GHS-R1a is considered to
signal via Gq and thus activates phospholipase C, which
results in increased inositol 1,4,5-triphosphate (IP3) and diacyl-
glycerol (DAG) levels. IP3 triggers the mobilization of free
calcium (Ca2) from the endoplasmatic reticulum and DAG
activates PKC. PKC inhibits K channels, and the following
depolarization causes an increased Ca2 current (10). In rodent
models ghrelin partitioned whole body metabolism toward the
utilization of glucose rather than fat (44) and decreased the
hepatic mitochondrial FFA uptake enzyme carnitine palmitoyl
transferase-1 (6). Together, those events may explain the pos-
itive inotropy observed in healthy humans, but specific cardi-
omyocyte ghrelin-signaling has not been fully elucidated and
the above described mechanisms remain to be documented in
myocardial tissue. Available in vitro data report that ghrelin
increases protein kinase B and ERK 1 and 2 phosphorylation in
H9c2 cardiomyocytes and improves cardiomyocyte survival
when coincubated with doxorubicin (5). In rodents, ghrelin
administration results in cardiac AMP-activated protein kinase
activity (28), which mediates insulin-independent glucose up-
take, thereby influencing cell metabolism. Our present study
conducted in healthy volunteers describes clinical effects of
ghrelin on the left ventricle function only. Future studies
should be performed to investigate the cardiac metabolic ef-
fects of ghrelin and in a future series of studies we aim to apply
PET technique to investigate these issues.
Decreased cardiac afterload by peripheral vasodilatation can
explain an increase in cardiac function. In this study, however,
ghrelin exerted no effects on either heart rate, arterial diameter,
resting blood flow velocity, or endothelium-dependent vasodi-
latation, when the radial artery was probed with a method that
previously has proven reliable (20), and, if anything, ghrelin
showed a tendency to decrease resting blood flow. We did not
record systemic blood pressure, which is a limitation of the
present study. The effect of ghrelin on blood pressure has,
however, been investigated in other clinical trials. Enomoto
et al. (14) injected three doses of ghrelin (1, 5, and 10 g/kg)
to humans, which resulted in 2-, 8-, and 12-fold increases of
baseline ghrelin values and no effect on mean arterial pressure.
In other trials, ghrelin levels were increased by 43- (34) and
61-fold increases (33), which resulted in a 9- and 12-mmHg
reduction in mean arterial blood pressure, respectively. In
comparison, the 6.7-fold increase of ghrelin compared with the
placebo value in this study is in the range with no expected
blood pressure effects. On the basis of existing literature we
had anticipated an endothelial-dependent vasodilation after
ghrelin (36, 42). Endothelial function is, however, also regu-
lated by metabolic cues. In particular, insulin resistance and
elevated levels of FFA may impair endothelium-dependent
vasodilatation (43, 46). We have recently observed that exog-
enous ghrelin induces acute insulin resistance in skeletal mus-
cle in concomitance with elevated FFA levels (unpublished
data). It is therefore plausible that ghrelin via both direct and
indirect mechanisms may exert reciprocal effects on endothe-
lial function. The roles of epinephrine, norepinephrine, and
soluble adhesion molecules are probably minor in the present
study, because the levels of all three hormones and markers of
endothelial activation were similar during both placebo and
ghrelin treatment. Indeed, insulin levels increased in the
present study, but the increase was only recorded when the
study was terminated.
OPG, a member of the tumor necrosis factor receptor super-
family, is expressed in arterial wall and increased in diabetic
patients. In this study, the infusion of ghrelin translated into
metabolic impairment in terms of elevated FFA levels, whereas
OPG levels were constant. It is of significant interest whether
ghrelin downregulates OPG in subjects expressing increased
levels of FFA and insulin, but our infusion period may be too
short to uncover augmented levels of OPG. Clearly, long-term
studies are needed to clarify this matter.
We also observed a significant increase in the circulating
levels of cortisol in response to ghrelin administration. The
effect of cortisol per se on left ventricular function in vivo is
largely unknown. A limited number of reports describe the role
of glucose and FFA on left ventricular function in vivo;
contractile function of the normal heart is not improved by an
acute increase in glucose uptake (39), and FFAs have no effect
on contractility in either chronically stunned, hibernating, or
control myocardial regions (49).
Well-known pharmacological effects of ghrelin include in-
creased systemic levels of GH, ACTH, cortisol, prolactin, and
epinephrine (33, 41), whereas more physiological ghrelin in-
crements (i.e., 2- to 3-fold elevations) usually have no signif-
icant effects on the levels of metabolites and hormones except
GH (2, 31, 52). We hypothesized that ghrelin stimulates
cardiovascular functions and the aim of this study was to
investigate the sustained effects of more moderate increments
in ghrelin levels compared with previous studies (14, 33–35).
We used a ghrelin dose of 5 pmol/kg per minute, correspond-
ing to approximately half-maximal GH stimulating dose (52).
Since a previous study showed that 2 h of ghrelin infusion at
7.5 pmol/kg per minute did not influence glucose, insulin,
IGF-I, cortisol, epinephrine, norepinephrine, or FFA levels,
and the GH response was most distinct within the first 90 min,
resolving thereafter (31), we were surprised to find an increase
in cortisol and FFAs in our study.
The present study is distinct from earlier studies in several
respects. First, earlier studies of the cardiac effects of ghrelin in
humans have used either invasive methods (33, 34) or echo-
cardiographically assessed left ventricular ejection fraction
(14, 35), which are both dependable on pre- and afterload
conditions. We used tissue Doppler imaging and TT tech-
niques, which are sensitive noninvasive methods for assessing
systolic tissue velocities and longitudinal displacement of the
myocardium (3). In addition, both measures are more reliable
indexes of the myocardial function rather than reflecting
changes in pre- and afterload conditions (37, 48). This is of
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significant interest because ghrelin administration has been
shown to decrease afterload (33, 34). Second, earlier studies
used very high supraphysiological or pharmacological ghrelin
doses (14, 33, 34). Third, the majority of earlier studies used
bolus administration of ghrelin (14, 22, 33, 35) instead of
a continuous infusion. Fourth, some of the previous studies
lacked a placebo group (22, 35). Finally, clinical studies of the
vasoactive effects of ghrelin used intra-arterial administration
(36, 42), whereas the present study reports the effects of
elevated systemic ghrelin levels.
Compensatory mechanisms suppress ghrelin levels in obe-
sity (19), and concomitant insulin resistance contributes to a
further suppression (32). Although correlation does not imply
causality, it is tempting to hypothesize that suppressed ghrelin
levels may contribute to the cardiovascular morbidity in obese
and insulin-resistant subjects. Conversely, weight loss in obese
patients, which increases circulating ghrelin levels (19), could
theoretically improve cardiac function. In a clinical setting,
treatment with ghrelin or one of its analogs could become a
future option for patients suffering from chronic heart failure
and cachexia.
The present study for the first time describes that in a
randomized, double-blind, placebo-controlled crossover study
supraphysiological ghrelin levels persistently throughout the
3-h study period stimulate left ventricular function, assessed by
a noninvasive technique, without changing endothelium-de-
pendent vasodilatation. The effects did, however, not translate
into detectable increments in ejection fraction, and a longer
infusion period would be needed to substantiate the potential
effect of ghrelin in chronic heart failure.
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